Ionis recognizes the importance of Independent Medical Education (IME) and is committed to supporting programs that seek to advance clinical care. Ionis supports targeted high-quality accredited and non-accredited medical education programs to advance excellence in healthcare by improving disease awareness, clinical knowledge, and multidisciplinary management within our therapeutic areas of focus.

IME is defined as education that is evidence-based, fair-balanced, unbiased, and independent of industry influence. Therefore, all aspects related to IME including but not limited to the agenda, content, and faculty, must remain fully independent and be under the sole control of the activity organizers. Ionis will not provide any guidance to the IME provider. All accredited programs must follow the standards set forth in the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education.

FUNDING PRIORITIES:

Requests with multiple potential supporters are preferred. Due to the number of requests received not all submitted requests will be approved or approved at the amount requested. Ionis will consider funding requests in the following therapeutic areas of focus for medical educational programs in the United States:

Areas of Focus

We are accepting grant applications for medical education programs within the United States for the following therapeutic areas:

Hereditary angioedema (HAE):

• Current treatment challenges related to long-term prophylaxis for HAE with a focus on recent real-world data
• Unmet needs of patients living with HAE
• The role of long-term prophylaxis in the management of HAE
• Investigational drugs in late-stage development for long-term prophylaxis of HAE with a focus on how the underlying targets may differentiate the drugs in development

Severe Hypertriglyceridemia including genetic conditions such as Familial Chylomicronemia Syndrome:

• Pathophysiology, disease burden, and management of elevated triglycerides
• Current treatment challenges and unmet needs of patients
• Investigational drugs in late-stage development

GRANT SUBMISSION PROCESS:

All IME grant request applications must be submitted through our online Ionis Medical Grants portal by clicking here: Apply Now. Please note that the Grant requests must be submitted at least 60 calendar days prior to the program/event start date.

The following elements will be required when submitting the online grant request application. The submitter will be able to save their work and continue at another time. In addition to the required fields on our application form, the submitter will have the opportunity to upload PDF documents of additional information which may be relevant or taken into consideration.

• Requesting Organization
• Program Title
• Program Description
• Needs Assessment
• Needs Assessment References
• Program Learning Objectives
• Information if program has been held previously
• Designation if program is affiliated with a congress
• Partner Organization Information
• Funding decision needed by date
• Program Start Date
• Program End Date
• Total Number of Activities Planned
• Activity Type (Live in Person, Live Virtual, Hybrid, Enduring)
• Activity Location
• Number of Speakers/Faculty Members
• Geographic Reach
• Activity Target Audience
• Expected Number of Attendees
• Expected Audience Information
• Audience Generation Tactics
• Activity Start/End Dates
• Accrediting Bodies and Number of Credit Hours
• Outcome Measures
• Detailed Budget
• Amount Requested from Ionis

Please note that the recipient of the grant must be an appropriate organization such as a hospital, university, school of medicine, nursing, or pharmacy, a professional society or association, a medical education communication company, or other institution specializing in specific healthcare-related disciplines (e.g., public health, quality improvement). Ionis does not support IME grant requests from healthcare providers, including individual physicians, private practice groups, group purchasing organizations, managed care organizations, preferred provider organizations, or similar institutions.

Note regarding grants in the ATTR therapeutic area

Global and United States IME grants requests for amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PM) will now be submitted to and reviewed by our global development and commercialization partner AstraZeneca. Please visit www.astrazenecagrants.com to review the application procedure and/or to submit.

MED-US-2300828 v3 5/2024

Overview

As a part of our commitment to discover, develop, and deliver medicines to the patients who depend on us, we believe in supporting investigator-initiated research (IIR) to advance medical and scientific knowledge in our research areas of interest.

We define IIR as unsolicited research conceived, initiated, and conducted independently of Ionis. An external investigator serves as the sponsor, and with their institution, is wholly responsible for the design, implementation, conduct of the research, data collection, data interpretation, publication, and all compliance, quality, and regulatory requirements.

IIR proposals are evaluated on scientific merit, alignment with our research areas of interest, and availability of resources. Submission of a proposal does not guarantee Ionis' support.

Research Areas of Interest

Cardiovascular/Metabolic

• Specific aspects of severe hypertriglyceridemia (sHTG) and familial chylomicronemia syndrome (FCS) disease, including:
  • Diagnosis and recognition of disease
  • Burden of disease
  • Unmet needs
  • Health economics
  • Patient experience
• Exploring the effects of sHTG and ApoC-III on the cardiovascular and endocrine systems
• Mode of action, potential pleiotropic effects, and biochemical pathways of ApoC-III regulation

How to submit an IIR grant application:

Please submit grant proposal applications through our online Ionis Research Grants portal by clicking here: Apply Now. If a proposal is of interest, a request for full protocol submission and detailed budget will be issued to enable final review.

The IIR proposal application will request the following details for submission:

• Research Study Title
• Background, Clinical Significance, and Rationale
• Specific Aims/Objectives
• Study Design
• Study Endpoints (Specify Primary, Secondary, and Exploratory)
• Safety Consideration
• Statistical Methodology
• Estimated Study Duration
• Potential Pitfalls and Contingencies
• References
• Estimated Total Study Budget
• Publication Plan
• Investigator’s CV and Medical License

MED-US-2300825 v2 5/2024

What is the CRM Ionis Young Investigator Grant (YIG)?

Ionis Pharmaceuticals is pleased to announce the Ionis CRM Young Investigator Grant (YIG). This grant was recently created by the division of CardioRenal-Metabolism within Medical Affairs to recognize early career investigators who are performing high quality research in the field of severe hypertriglyceridemia. Ionis values developing clinicians and scientists who will influence the field and support new research for years to come.

Who is eligible?

The Ionis CRM YIG is a grant aimed at providing research grants to fellows who are at eligible academic or non-profit institutions and submit innovative research proposals in the areas of translational, clinical, or applied research. The Ionis CRM YIG encourages early stage scientific investigators of promise to apply, who are engaged in cutting-edge research on the topic of severe hypertriglyceridemia for the following categories:

• Clinical investigations
• Basic and Translational Science
• Outcomes Research (and/or EMR-related research)

The goals of the research application should focus on understanding the effects of chylomicron and/or triglyceride elevations on cardiovascular and metabolic disease. Specifically, the grant will support a fellow, resident, or junior faculty annually to promote quality research and support the development of future researchers and clinicians.

Overview

This grant is awarded by an independent review committee on a competitive basis for a maximum of two academic years with the first year guaranteed and the second-year contingent on approval of a progress submission demonstrating progress towards the pre-stated research objectives and ongoing research.

Deadlines and important dates based on grant program approval

• Application deadline – Monday, June 17, 2024

Late submissions or incomplete applications will not be considered.

• Award notification – Wednesday, July 17, 2024

Grant recipients and their affiliated institutions receive grant notification.

• Acceptance of contract – Monday, September 16, 2024

Grant acceptance must be signed by investigator, mentor, and institution and returned to receive grant funds.

CRM Young Investigator Grant funds

• The CRM Young Investigator Grant will be paid directly to the grantee’s institution
• Grant will be funded in the amount of $50,000 per year and may be renewable for a second year at the same level provided sufficient progress has been made towards the research objectives and with approval of a progress submission demonstrating progress and ongoing research
• The grant may be transferred to another investigator if needed upon renewal for the second year after approval from Ionis (ex. after completion of 1-year fellowship)
• Grant may only be used as described in the granted proposal submission
• Institution is not limited in the amount of additional support it may provide the investigator
• Submissions duplicative of other research, prior submissions of Investigator sponsored studies, or projects focused on competitor products are not eligible for the CRM Young Investigator Grant Program

Applicant eligibility and qualifications

• Mentors may submit the application on behalf of the investigator if not yet selected; this will allow the institution to know if funding has been secured to support a fellowship position in advance
• Investigator must hold a doctorate degree during the grant period
• Investigator may not have more than 3 years of post-doctoral research experience
• Investigators working full-time and currently in training are eligible to apply, including residents
• Applicants with existing tenure-track research positions or senior faculty appointments are ineligible
• Investigator must be either a United States citizen, in possession of a current student visa or a permanent alien resident, specifically:
  • US Citizen
  • Green Card - permanent residency visa – unlimited duration, can lead to US Citizenship
  • H1B Visa - the primary US Work Visa for professionals & students from all over the world or in the USA, who work in specialty occupations. Valid up to 6 years, dual intent visa (can apply for Green Card)
  • E3 Visa - similar to the H1B but is available to Australian Citizens only
  • TN1 Visa - similar to the H1B but is available to Canadian & Mexican Citizens only
  • J1 Visa (must be valid until January 2027)

CRM Young Investigator program requirements

• Funded research must be conducted in an academic or non-profit institution
• Grant should broaden the postdoctoral research experience of the young investigator and not be used for further support of preexisting and extensive postdoctoral research training
• Funded research must be conducted under the supervision of an experienced mentor at the sponsoring institution
• Proposed research must have anticipated completion timeline of 2 years or less
• The grant cannot be transferred to an alternate investigator or institution in the event the original institution and investigator dissolve their association without approval by Ionis
• Ionis Medical Affairs must be notified, in writing with appropriate justification, immediately if the sponsoring institution anticipates any delay of the term
• Expected Outcomes: submission of data for external presentation and/or publication within 2 years of initial funding

Application materials

The following must be submitted via email to ionisgrants@ionis.com to apply:

1. Grant request letter

   Must be on institutional letterhead, written and signed by the Department Chair, Division Chief or Training Program Director and include:

   • Academic term dates for investigator’s current position if applicable (e.g., July 1, 2024 to June 30, 2026)
   • Statement of:
     • mentor’s qualifications to supervise and train the investigator
     • scientific prowess of the institution
     • institutional commitment to advancing the care of patients with cardiology or metabolic disease
2. Current curriculum vitae or NIH biosketch
   • Mentor (required)
   • Investigator (required if known)
3. Research proposal (preferably not to exceed 5 pages) to include:
   • Introduction, research objectives and rationale
   • Background and significance
   • Specific area of research
   • Preliminary data (if available)
   • Design and methods (including statistical analyses)
   • Patient population
   • Investigator’s role in design and execution of research proposal
   • Detailed budget, including other funding sources (if applicable)
   • References

4. Letter of support from mentor

   • Detail the eligibility, scientific skills, and background of the investigator and how the grant would be beneficial for the development of this young investigator

   OR, if investigator not yet identified,

   • Describe the selection process for identifying an investigator to complete the funded research and how the grant would be beneficial at his/her institution for developing a young investigator
5. Formal brochure/overview of training program or department

MED-US-2300913 v3 6/2024

What is the Ionis Young Investigator Grant (YIG)?

Ionis Pharmaceuticals is pleased to announce the Ionis YIG. This grant was recently created within Medical Affairs to recognize early career investigators who are performing high quality research in HAE. Ionis values developing clinicians and scientists who will influence the field and support new research for years to come.

Who is eligible?

The Ionis YIG is a grant aimed at providing research grants to fellows who are at eligible academic or non-profit institutions and submit innovative research proposals in the areas of translational, clinical, or applied research. The Ionis YIG encourages early-stage scientific investigators of promise to apply, who are engaged in cutting-edge research on the topic of HAE for the following categories:

• Clinical investigations
• Basic and Translational Science
• Outcomes Research (and/or EMR-related research)

The research should focus on understanding the current challenges of acute and prophylactic treatments in HAE or understanding the pathophysiology of HAE. Specifically, the grant will support two fellows, residents, or junior faculty annually to promote quality research and support the development of future researchers and clinicians.

Overview

This grant is awarded by an independent review committee on a competitive basis for a maximum of two academic years with the first year guaranteed and the second-year contingent on approval of a progress submission demonstrating progress towards the pre- stated research objectives and ongoing research.

Deadlines and important dates based on grant program approval

• Application deadline – April 1, 2025

Late submissions or incomplete applications will not be considered.

• Award notification – May 2, 2025

Grant recipients and their affiliated institutions receive grant notification.

• Acceptance deadline – July 15, 2025

Grant acceptance must be signed by investigator, mentor, and institution and returned to receive grant funds.

Young investigator Grant funds

• The Young Investigator Grant will be paid directly to the grantee’s institution
• Grant will be funded in the amount of $50,000 per year and may be renewable for a second year at the same level provided sufficient progress has been made towards the research objectives and with approval of a progress submission demonstrating progress and ongoing research
• The grant may be transferred to another investigator if needed upon renewal for the second year after approval from Ionis (ex. after completion of 1-year fellowship)
• Grant may only be used as described in the granted proposal submission
• Institution is not limited in the amount of additional support it may provide the investigator
• Submissions duplicative of other research, prior submissions of Investigator sponsored studies, or projects focused on competitor products are not eligible for the YIG Grant Program

Applicant eligibility and qualifications

• Mentors may submit the application on behalf of the investigator if not yet selected; this will allow the institution to know if funding has been secured to support a fellowship position in advance
• Investigator must hold a doctorate degree during the grant period
• Investigator may not have more than 5 years of post-doctoral research experience
• Investigators working full-time and currently in training are eligible to apply, including residents
• Applicants with existing tenure-track research positions or senior faculty appointments are ineligible
• Investigator must be either a United States citizen, in possession of a current student visa or a permanent alien resident, specifically:
  • US Citizen
  • Green Card - permanent residency visa – unlimited duration, can lead to US Citizenship
  • H1B Visa - the primary US Work Visa for professionals & students from all over the world or in the USA, who work in specialty occupations. Valid up to 6 years, dual intent visa (can apply for Green Card)
  • E3 Visa - similar to the H1B but is available to Australian Citizens only
  • TN1 Visa - similar to the H1B but is available to Canadian & Mexican Citizens only
  • J1 Visa (must be valid until January 2027)

Young Investigator Grant program requirements

• Funded research must be conducted in an academic or non-profit institution
• Grant should broaden the postdoctoral research experience of the young investigator and not be used for further support of preexisting and extensive postdoctoral research training
• Funded research must be conducted under the supervision of an experienced mentor at the sponsoring institution
• Proposed research must have anticipated completion timeline of 2 years or less
• The grant cannot be transferred to an alternate investigator or institution in the event the original institution and investigator dissolve their association without approval by Ionis
• Ionis Medical Affairs must be notified, in writing with appropriate justification, immediately if the sponsoring institution anticipates any delay of the term
• Expected Outcomes: submission of data for external presentation and/or publication within 2 years of initial funding

Application materials

The following must be submitted via email to ionisgrants@ionis.com to apply:

1. Grant request letter

   Must be on institutional letterhead, written and signed by the Department Chair, Division Chief or Training Program Director and include:

   • Academic term dates for investigator’s current position if applicable (e.g., July 1, 2024 to June 30, 2026)
   • Statement of:
     • mentor’s qualifications to supervise and train the investigator
     • scientific prowess of the institution
     • institutional commitment to advancing the care of patients with HAE
2. Current curriculum vitae or NIH biosketch
   • Mentor (required)
   • Investigator (required if known)
3. Research proposal (preferably not to exceed 5 pages) to include:
   • Introduction, research objectives, and rationale
   • Background and significance
   • Specific area of research
   • Preliminary data (if available)
   • Design and methods (including statistical analyses)
   • Patient population
   • Investigator’s role in design and execution of research proposal
   • Detailed budget, including other funding sources (if applicable)
   • References

4. Letter of support from mentor

   • Detail the eligibility, scientific skills, and background of the investigator and how the grant would be beneficial for the development of this young investigator.

   OR, if investigator not yet identified,

   • Describe the selection process for identifying an investigator to complete the funded research and how the grant would be beneficial at his/her institution for developing a young investigator
5. Formal brochure/overview of training program or department

MED-US-2301033 v3 6/2024

What is the Ionis Neurology Young Investigator Grant?

Ionis Pharmaceuticals is pleased to announce the Ionis Neurology Young Investigator Grant (YIG). This grant was recently created by the Division of Neurology within Medical Affairs to advance high-quality research in the field of Alexander Disease by early career investigators. Ionis is dedicated to developing clinicians and scientists who will positively impact the field and support new research for years to come.

Who is eligible?

The Ionis YIG is a grant aimed at providing research grants to fellows who are at eligible academic or non-profit institutions and submit innovative research proposals in the areas of translational, clinical, or applied research. The Ionis YIG encourages applications from early-stage scientific investigators who are engaged in cutting-edge research on the topic of leukodystrophies, with a focus on Alexander Disease, for the following categories:

• Clinical investigations
• Basic and Translational Science
• Outcomes Research (and/or EMR-related research)

Specifically, the grant will support 2 fellows, residents, or junior faculty annually (for up to 2 years) to conduct quality research and the development of future researchers and clinicians.

Objective

The objective of the program is to provide grants to researchers at eligible academic or nonprofit institutions who submit innovative research proposals in the areas of translational, clinical, or applied research. The research should advance the understanding of Alexander Disease, facilitate early diagnosis of patients, identify undiagnosed/misdiagnosed patients, and/or enhance the management of patients. Research in other leukodystrophies will be considered, however, the proposal should highlight the relevance of the work to Alexander Disease. Specifically, this program will support two young investigators, such as current fellows, residents, or junior faculty, with an award of $50,000 annually per awardee for up to two years.

Overview

This grant is awarded by an independent review committee on a competitive basis for a maximum of two academic years with the first year guaranteed and the second-year contingent on approval of a progress submission demonstrating progress towards the pre-stated research objectives and ongoing research.

Deadlines and important dates based on grant program approval

• Application deadline – April 1, 2025

Late submissions or incomplete applications will not be considered.

• Award notification – May 2, 2025

Grant recipients and their affiliated institutions receive grant notification.

• Acceptance of contract – July 15, 2025

Grant acceptance must be signed by investigator, mentor, and institution and returned to receive grant funds.

Young investigator Grant funds

• The Young Investigator Grant will be paid directly to the grantee’s institution. Requesting organization must be legally able to receive award funding directly from Ionis. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Ionis may be subject to rescission.
• Grant will be funded in the amount of $50,000 per year and may be renewable for a second year at the same level provided sufficient progress has been made towards the research objectives and with approval of a progress submission demonstrating progress and ongoing research
• The grant may be transferred to another investigator if needed upon renewal for the second year after approval from Ionis (ex. after completion of 1-year fellowship)
• Grant may only be used as described in the granted proposal submission
• Institution is not limited in the amount of additional support it may provide the investigator
• Submissions duplicative of other research, prior submissions of Investigator sponsored studies, or projects focused on competitor products are not eligible for the Young Investigator Grant Program

Applicant eligibility and qualifications

• Mentors may submit the application on behalf of the investigator if not yet selected; this will allow the institution to know if funding has been secured to support a fellowship position in advance
• Investigator must hold a doctorate degree during the grant period
• Investigator may not be more than 5 years post training/fellowship/residency
• Investigators working full-time and currently in training are eligible to apply, including residents
• Applicants with existing tenure-track research positions or senior faculty appointments are ineligible
• Applicants employed or affiliated with a government institution are ineligible

Young investigator program requirements

• Funded research must be conducted in an academic or non-profit institution
• Grant should broaden the postdoctoral research experience of the young investigator and not be used for further support of preexisting and extensive postdoctoral research training
• Funded research must be conducted under the supervision of an experienced mentor at the sponsoring institution
• Proposed research must have anticipated completion timeline of 2 years or less
• The grant cannot be transferred to an alternate investigator or institution in the event the original institution and investigator dissolve their association without approval by Ionis
• Ionis Medical Affairs must be notified, in writing with appropriate justification, immediately if the sponsoring institution anticipates any delay of the term
• Expected Outcomes: submission of data for external presentation and/or publication within 2 years of initial funding

Application materials

The following must be submitted via email to ionisgrants@ionis.com to apply:

1. Grant request letter

   Must be on institutional letterhead, written and signed by the Department Chair, Division Chief or Training Program Director and include:

   • Academic term dates for investigator’s current position if applicable (e.g., July 1, 2024 to June 30, 2026)
   • Statement of:
     • mentor’s qualifications to supervise and train the investigator
     • scientific prowess of the institution
     • institutional commitment to advancing the care of patients with cardiology or metabolic disease
2. Current curriculum vitae or NIH biosketch
   • Mentor (required)
   • Investigator (required if known)
3. Research proposal (preferably not to exceed 5 pages) to include:
   • Introduction, research objectives and rationale
   • Background and significance
   • Specific area of research
   • Preliminary data (if available)
   • Design and methods (including statistical analyses)
   • Patient population
   • Investigator’s role in design and execution of research proposal
   • Detailed budget, including other funding sources (if applicable)
   • References

4. Letter of support from mentor

   • Detail the eligibility, scientific skills, and background of the investigator and how the grant would be beneficial for the development of this young investigator

   OR, if investigator not yet identified,

   • Describe the selection process for identifying an investigator to complete the funded research and how the grant would be beneficial at his/her institution for developing a young investigator
5. Formal brochure/overview of training program or department

MED-US-2300916 v3 6/2024